Weekly Anesthesiology Research Analysis
This week’s anesthesiology literature highlights three high-impact advances: (1) a BMJ systematic review establishes an evidence hierarchy for non‑drug perioperative interventions to reduce postoperative pulmonary complications after abdominal surgery; (2) a randomized trial in BMC Medicine shows early postoperative rTMS halves chronic postsurgical pain after thoracoscopic surgery and links benefit to lower CXCL10 levels; and (3) a Cellular Signalling mechanistic study identifies an HDAC7–NF-κB–
Summary
This week’s anesthesiology literature highlights three high-impact advances: (1) a BMJ systematic review establishes an evidence hierarchy for non‑drug perioperative interventions to reduce postoperative pulmonary complications after abdominal surgery; (2) a randomized trial in BMC Medicine shows early postoperative rTMS halves chronic postsurgical pain after thoracoscopic surgery and links benefit to lower CXCL10 levels; and (3) a Cellular Signalling mechanistic study identifies an HDAC7–NF-κB–MFN2–ACSL4 ferroptosis pathway driving perioperative neurocognitive disorders in aged mice, pointing to druggable targets. Together these papers push prevention (non-pharmacologic bundles, neuromodulation), mechanism-informed targeting (ferroptosis), and biomarker‑linked risk stratification toward clinical translation.
Selected Articles
1. Non-drug perioperative interventions to reduce postoperative pulmonary complications after abdominal surgery: systematic review and meta-analysis.
Comprehensive synthesis of 255 RCTs (55,260 participants) across 10 intervention classes evaluated non‑drug perioperative strategies to prevent postoperative pulmonary complications after abdominal surgery, using trial sequential analysis and GRADE to produce an evidence hierarchy and prioritize implementable measures (e.g., oxygen fraction strategies among higher‑certainty domains).
Impact: Establishes the most rigorous, GRADE‑and‑TSA‑based prioritization of non‑pharmacologic perioperative interventions to reduce PPCs, directly informing anesthesia‑led ERAS and respiratory care bundles.
Clinical Implications: Clinicians and institutions should use the evidence hierarchy to prioritize and standardize perioperative systems and respiratory strategies (e.g., targeted FiO2, physiotherapy/early mobilization, standardized incentive spirometry and PEEP protocols) to reduce postoperative pulmonary complications after abdominal surgery.
Key Findings
- Synthesized 255 randomized trials (55,260 participants) across 10 intervention categories and 39 subtypes for PPC prevention after abdominal surgery.
- Overall PPC incidence across trials was 11.7%, enabling benchmarking for quality initiatives.
- Applied Trial Sequential Analysis and GRADE to generate an evidence hierarchy; certain oxygenation strategies were among higher-certainty domains.
2. Early repetitive transcranial magnetic stimulation for preventing chronic postoperative pain in older adults: a randomized clinical sub-study.
In a randomized, sham‑controlled trial of thoracoscopic surgery patients aged mainly older adults (n≈230 randomized; 198 completed 3‑month follow‑up), a single early postoperative DLPFC‑targeted rTMS session reduced 3‑month CPSP incidence (24.3% vs 43.5%; RR 0.56) and improved anxiety/depression scores; serum CXCL10 was lower after active rTMS and showed high predictive accuracy for CPSP (AUC 0.90).
Impact: First randomized evidence that a noninvasive neuromodulation session delivered immediately postoperatively can substantially reduce CPSP and link clinical benefit to an inflammation biomarker (CXCL10), offering a scalable prevention strategy.
Clinical Implications: Consider incorporation of early rTMS protocols as an adjunct to multimodal analgesia for high‑risk thoracoscopic patients pending replication; explore CXCL10 as a risk stratification biomarker to target interventions.
Key Findings
- Active rTMS reduced CPSP at 3 months (24.3% vs 43.5%; RR 0.56; P=0.002).
- Anxiety and depression scores improved at 3 months with rTMS.
- Serum CXCL10 levels were lower after active rTMS and strongly predicted CPSP (AUC 0.90).
3. Hippocampal HDAC7 induces perioperative neurocognitive disorders via an NF-κB-MFN2-ACSL4 ferroptosis pathway.
In an aged mouse tibial fracture model, hippocampal HDAC7 and phosphorylated NF-κB rose after surgery. AAV‑shRNA knockdown of HDAC7 reduced NF-κB activation, improved mitochondrial integrity, restored MFN2, reversed ACSL4 upregulation and GPX4 loss, and normalized ferroptosis markers—implicating an HDAC7–NF‑κB–MFN2–ACSL4 ferroptosis axis in perioperative neurocognitive disorders.
Impact: Defines a druggable molecular axis (HDAC7→NF‑κB→MFN2→ACSL4) linking surgery to ferroptotic neuronal injury and perioperative cognitive decline, providing concrete mechanistic targets for preventive pharmacology.
Clinical Implications: Supports preclinical prioritization of HDAC7/NF-κB/ferroptosis inhibitors or mitochondrial‑protective agents to prevent perioperative neurocognitive disorders in older adults; encourages biomarker development and early-phase translational trials.
Key Findings
- Surgery increased hippocampal HDAC7 and phosphorylated NF-κB in aged mice at day 3 post-op.
- AAV-shRNA knockdown of HDAC7 reduced NF-κB activation, ameliorated mitochondrial damage, and restored MFN2 expression.
- Ferroptosis markers (ACSL4 up, GPX4 loss) were reversed by HDAC7 knockdown, implicating an NF-κB–MFN2–ACSL4 ferroptosis pathway in PND.